Rrx-001

Advanced Cancer

EpicentRx, Inc.Phase 1Dormant

C

38/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 26/ 100
Competitive Position: 73/ 100

Competitive context

1412 Active assets in the Advanced Cancer cohort.

Asset / Sponsor	Phase	Rating
Nabiximols Jazz Pharmaceuticals	Phase 3	BBB
Inno-206 M.D. Anderson Cancer Center	Phase 2	BB
Vitamin B6 M.D. Anderson Cancer Center	Phase 4	BB
PROPOFOL Hong Kong Children's Hospital	Phase 4	BB
Rivoceranib Jiangsu HengRui Medicine Co., Ltd.	Phase 4	BB

View all 50 →

Same molecule, other indications

Rrx-001 is also rated in:

small cell lung carcinomaDormant

CCC

Indicative ·

51 / 100

colorectal neoplasmDormant

CCC

Indicative ·

49 / 100

small cell carcinomaDormant

CCC

Indicative ·

49 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.